An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT02676401

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02676401
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02676401. Randomized; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2017-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
MT-3995 Low
Intervention (Drug)
MT-3995 Middle
Intervention (Drug)
MT-3995 High
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02676401
Content hash
2b56ce1169f905d2cdbc511c120730860b9326e560d072c71049004a25942a8e